Moderate Alzheimer'
Conditions
Interventions
Memantine FDG-PET and SPECT scans at the visit of screening, 12 weeks, 52 weeks
Sponsors
Sunagawa City Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have signed the informed consent form 2) Are <= 50 years of age 3) Japanese, regardless of sex 4) Fulfills both of the criteria below - Alzheimer's disease according to DSM-5 - All-cause dementias and probable AD dementia according to NIA-AA criteria 5) Patient whose CT/MRI and SPECT within 1 month prior to signing informed consent results show as AD 6) Screening MMSE score of 14 to 19 7) Untreated AD patient before enrolled in this study ...etc.
Exclusion criteria
Exclusion criteria: 1) Dementia other than AD 2) Significant neurologic desease 3) Other muscloskeletal complication which may affects implementing cognitive assessments 4) Significant psychiatric disorder 5) History of alcoholism or drug addiction 6) History of severe drug allegy 7) Other clinically important or uncontrolled diseases at the time of screening 8) Use of investigational medications within 60 days prior to screening etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FDG-PET, SPECT, MMSE and NPI after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| - FDG-PET, SPECT, MMSE and NPI after 52 weeks - Safety information | — |
Countries
Japan
Contacts
Public ContactTadahiro Hashida
Micron Inc. Clinical Research Department
Outcome results
None listed